^
    Back
    Association details:
    Biomarker:SRSF2 mutation
    Cancer:Myelodysplastic Syndrome
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Myelodysplastic…Subtype...CMML-2…Frequent mutations...TET2, SRSF2, ASXl1, RUNX1, NRAS, CBL…HMA ± ruxolitinib…